Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) research and antiviral discovery are hampered by the lack of a cell-based virus replication system that can be readily adopted without biosafety level 3 (BSL-3) restrictions. Here, the construction of a noninfectious SARS-CoV-2 reporter replicon and its application in deciphering viral replication mechanisms and evaluating SARS-CoV-2 inhibitors are presented. The replicon genome is replication competent but does not produce progeny virions. Its replication can be inhibited by RdRp mutations or by known SARS-CoV-2 antiviral compounds. Using this system, a high-throughput antiviral assay has also been developed. Significant differences in potencies of several SARS-CoV-2 inhibitors in different cell lines were observed, which highlight the challenges of discovering antivirals capable of inhibiting viral replication in vivo and the importance of testing compounds in multiple cell culture models. The generation of a SARS-CoV-2 replicon provides a powerful platform to expand the global research effort to combat COVID-19.
Severe acute respiratory syndrome coronavirus 2 (pan class="Species">SARS-CoV-2) research and antiviral discovery are hampered by the lack of a cell-based virus replication system that can be readily adopted without biosafety level 3 (BSL-3) restrictions. Here, the construction of a noninfectious SARS-CoV-2 reporter replicon and its application in deciphering viral replication mechanisms and evaluating SARS-CoV-2 inhibitors are presented. The replicon genome is replication competent but does not produce progeny virions. Its replication can be inhibited by RdRp mutations or by known SARS-CoV-2 antiviral compounds. Using this system, a high-throughput antiviral assay has also been developed. Significant differences in potencies of several SARS-CoV-2 inhibitors in different cell lines were observed, which highlight the challenges of discovering antivirals capable of inhibiting viral replication in vivo and the importance of testing compounds in multiple cell culture models. The generation of a SARS-CoV-2 replicon provides a powerful platform to expand the global research effort to combat COVID-19.
Authors: Inna Ricardo-Lax; Joseph M Luna; Tran Thi Nhu Thao; Jérémie Le Pen; Yingpu Yu; H-Heinrich Hoffmann; William M Schneider; Brandon S Razooky; Javier Fernandez-Martinez; Fabian Schmidt; Yiska Weisblum; Bettina Salome Trüeb; Inês Berenguer Veiga; Kimberly Schmied; Nadine Ebert; Eleftherios Michailidis; Avery Peace; Francisco J Sánchez-Rivera; Scott W Lowe; Michael P Rout; Theodora Hatziioannou; Paul D Bieniasz; John T Poirier; Margaret R MacDonald; Volker Thiel; Charles M Rice Journal: Science Date: 2021-10-14 Impact factor: 47.728
Authors: Thanigaimalai Pillaiyar; Philipp Flury; Nadine Krüger; Haixia Su; Laura Schäkel; Elany Barbosa Da Silva; Olga Eppler; Thales Kronenberger; Tianqing Nie; Stephanie Luedtke; Cheila Rocha; Katharina Sylvester; Marvin R I Petry; James H McKerrow; Antti Poso; Stefan Pöhlmann; Michael Gütschow; Anthony J O'Donoghue; Yechun Xu; Christa E Müller; Stefan A Laufer Journal: J Med Chem Date: 2022-06-16 Impact factor: 8.039
Authors: Hu Zhang; Douglas K Fischer; Masahiro Shuda; Patrick S Moore; Shou-Jiang Gao; Zandrea Ambrose; Haitao Guo Journal: J Med Virol Date: 2022-02-19 Impact factor: 20.693
Authors: Kirill Gorshkov; Desarey Morales Vasquez; Kevin Chiem; Chengjin Ye; Bruce Nguyen Tran; Juan Carlos de la Torre; Thomas Moran; Catherine Z Chen; Luis Martinez-Sobrido; Wei Zheng Journal: ACS Pharmacol Transl Sci Date: 2022-01-03
Authors: Abhijit Basu; Srinivasa Penumutchu; Kien Nguyen; Uri Mbonye; Blanton S Tolbert; Jonathan Karn; Anton A Komar; Barsanjit Mazumder Journal: J Virol Date: 2021-11-10 Impact factor: 5.103
Authors: Ulrik Fahnøe; Long V Pham; Carlota Fernandez-Antunez; Rui Costa; Lizandro René Rivera-Rangel; Andrea Galli; Shan Feng; Lotte S Mikkelsen; Judith M Gottwein; Troels K H Scheel; Santseharay Ramirez; Jens Bukh Journal: Viruses Date: 2022-01-18 Impact factor: 5.048
Authors: Matthew D Hall; James M Anderson; Annaliesa Anderson; David Baker; Jay Bradner; Kyle R Brimacombe; Elizabeth A Campbell; Kizzmekia S Corbett; Kara Carter; Sara Cherry; Lillian Chiang; Tomas Cihlar; Emmie de Wit; Mark Denison; Matthew Disney; Courtney V Fletcher; Stephanie L Ford-Scheimer; Matthias Götte; Abigail C Grossman; Frederick G Hayden; Daria J Hazuda; Charlotte A Lanteri; Hilary Marston; Andrew D Mesecar; Stephanie Moore; Jennifer O Nwankwo; Jules O'Rear; George Painter; Kumar Singh Saikatendu; Celia A Schiffer; Timothy P Sheahan; Pei-Yong Shi; Hugh D Smyth; Michael J Sofia; Marla Weetall; Sandra K Weller; Richard Whitley; Anthony S Fauci; Christopher P Austin; Francis S Collins; Anthony J Conley; Mindy I Davis Journal: J Infect Dis Date: 2021-07-15 Impact factor: 7.759
Authors: Chamandi S Dampalla; Jian Zheng; Krishani Dinali Perera; Lok-Yin Roy Wong; David K Meyerholz; Harry Nhat Nguyen; Maithri M Kashipathy; Kevin P Battaile; Scott Lovell; Yunjeong Kim; Stanley Perlman; William C Groutas; Kyeong-Ok Chang Journal: Proc Natl Acad Sci U S A Date: 2021-07-20 Impact factor: 12.779
Authors: Kirill Gorshkov; Desarey Morales Vasquez; Kevin Chiem; Chengjin Ye; Bruce Nguyen Tran; Juan Carlos de la Torre; Thomas Moran; Catherine Z Chen; Luis Martinez-Sobrido; Wei Zheng Journal: bioRxiv Date: 2021-07-05